review of glp 1 Glucagon-like peptide-1 receptor agonists and risk gastrointestinal cancers: A systematic and meta-analysis of randomized controlled trials New research is taking a

Recent FDA approvals have included indications for cardiovascular risk reduction, and others are anticipated for conditions like obstructive sleep apnea and chronic kidney disease

This imbalance is hypothesized to contribute to dysfunctions in the reward system, potentially manifesting as anhedonia and other depressive symptoms 45 , a clinical observation that aligns with the psychiatric side effects noted in GLP-1 RAs therapy

Thats too bad, since theyre high in fibre, which boosts overall health

At UAB, scientists are working to understand not just that these medications work, but how they work: how they act in the brain, how they affect multiple organs at once, why some patients respond better than others and what next-generation versions of these drugs might look like